- Home
- NVAX vs MGNI Comparison
NVAX vs MGNI Comparison
Compare NVAX & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- MGNI
- Stock Information
- Founded
- NVAX 1987
- MGNI 2007
- Country
- NVAX United States
- MGNI United States
- Employees
- NVAX N/A
- MGNI N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- MGNI Computer Software: Programming Data Processing
- Sector
- NVAX Health Care
- MGNI Technology
- Exchange
- NVAX Nasdaq
- MGNI Nasdaq
- Market Cap
- NVAX 2.0B
- MGNI 1.7B
- IPO Year
- NVAX 1995
- MGNI N/A
- Fundamental
- Price
- NVAX $9.76
- MGNI $12.94
- Analyst Decision
- NVAX Buy
- MGNI Strong Buy
- Analyst Count
- NVAX 6
- MGNI 11
- Target Price
- NVAX $17.83
- MGNI $16.95
- AVG Volume (30 Days)
- NVAX 7.2M
- MGNI 1.3M
- Earning Date
- NVAX 11-07-2024
- MGNI 11-07-2024
- Dividend Yield
- NVAX N/A
- MGNI N/A
- EPS Growth
- NVAX N/A
- MGNI N/A
- EPS
- NVAX N/A
- MGNI N/A
- Revenue
- NVAX $987,667,000.00
- MGNI $649,216,000.00
- Revenue This Year
- NVAX N/A
- MGNI $0.26
- Revenue Next Year
- NVAX N/A
- MGNI $10.75
- P/E Ratio
- NVAX N/A
- MGNI N/A
- Revenue Growth
- NVAX N/A
- MGNI 7.50
- 52 Week Low
- NVAX $3.53
- MGNI $6.46
- 52 Week High
- NVAX $23.86
- MGNI $15.92
- Technical
- Relative Strength Index (RSI)
- NVAX 36.20
- MGNI 54.59
- Support Level
- NVAX $9.52
- MGNI $12.35
- Resistance Level
- NVAX $10.63
- MGNI $13.11
- Average True Range (ATR)
- NVAX 0.57
- MGNI 0.42
- MACD
- NVAX -0.12
- MGNI 0.11
- Stochastic Oscillator
- NVAX 9.97
- MGNI 63.58
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
About MGNI Magnite Inc.
Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.